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Background/Aims: This study analyzed the scale and trends of the social and economic costs of liver disease in Korea for 
the past 5 years. Methods: The social aspects of socioeconomic costs were projected for viral hepatitis (B15-B19), liver 
cirrhosis, malignant neoplasm of the liver (C22) and other liver diseases (K70-K76), as representative diseases by dividing 
costs into direct and indirect from 2004 to 2008. Direct costs include hospitalization, outpatient, and pharmacy costs in the 
health-care sector, and transportation and caregiver costs. Indirect costs include the future income loss due to premature 
death and the loss of productivity resulting from absence from work. Results: The social and economic costs of liver 
disease were projected to be KRW 5,858 billion in 2004, KRW 5,572 billion in 2005, KRW 8,104 billion in 2006, 
KRW 6,095 billion in 2007, and KRW 5,689 billion in 2008. The future income loss resulting from premature death is thus 
greatest, from 73.9% to 86.1%, followed by the direct medical costs, from 9.0% to 18.1%. The productivity loss resulting 
from absence from work accounts for 3.3-5.5%, followed by the direct nonmedical costs such as transportation and 
caregiver costs, at 1.5-2.5%. Conclusions: Among the socioeconomic costs of liver disease in Korea, the future income 
loss resulting from premature death is showing a decreasing trend, whereas direct medical costs are increasing 
dramatically. (Korean J Hepatol 2011;17:274-291)
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INTRODUCTION
As the human life span has been extended with the 
development of medicine, chronic diseases rather than acute 
ones have been increasing. Because it is hard to cure chronic 
liver disease completely and it should be controlled well for 
life, patients and their family members bear various burdens. 
Liver disease, one of the most representative chronic diseases, 
has showed a high prevalence rate in the East including 
South Korea and it includes chronic hepatitis, hepatic 
cirrhosis and hepatocellular carcinoma (HCC). 
Liver disease ranked the eighth among causes of death in 
South Korea in 2009, and 6,868 died of liver disease for the 
one year.1 It recorded adds the cause of fifth in males and did 
third in persons in their 40s. Moreover, the mortality rate of 
HCC showed the second highest level by following lung 
cancer and it did the highest in persons in their 40s and 50s.1 
In particular, a study estimating socioeconomic costs of 
major cause of death in South Korea revealed that the loss of 
productivity caused by premature death due to chronic liver 
disease ranked second next to that of cancer.2 The high 
mortality of liver disease in economically active persons in 
their 40s and 50s means that the importance of liver disease 
management should be recognized by considering that 
chronic liver disease influences not only individuals or 
families but also the productivity of a society.3
The cost of illness is one of the most initial economic 
evaluation methods in the healthcare and it aims to measure 
the economic burden of illness in a society in terms of 
the consumption of healthcare resources and the loss of 
productivity.4 In addition, studies on the cost of illness 
suggest the negative influence of illness and injury by using 
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Table 1. Categories of liver disease
Types of diseases (ICD-10 codes) Sub-types of diseases (ICD-10 codes)
Viral hepatitis (B15-B19) Acute hepatitis A (B15)
Acute hepatitis B (B16)
Other acute viral hepatitis (B17)
Chronic viral hepatitis (B18)
Unspecified viral hepatitis (B19)
Liver cirrhosis and other liver diseases (K70-K76) Alcoholic liver disease (K70)
Toxic liver disease (K71)
Hepatic failure, NEC (K72)
Chronic hepatitis, NEC (K73)
Fibrosis and cirrhosis of liver (K74)
Other inflammatory liver diseases (K75)
Other diseases of liver (K76)
Malignant neoplasm of liver (C22) Malignant neoplasm of liver and intrahepatic bile ducts (C22)
a monetary unit which is a universal language of decision- 
makers and policy-makers. However, their results can 
provoke a considerable difference by countries, a base year 
for estimation, types of disease, cost items, formulas for 
estimation and data for analysis among researchers and can 
have problem relating to validity or reliability.5,6 Nonetheless, 
studies on the cost of illness have been utilized as important 
indexes to prioritize the economic burdens of specific 
diseases, to determine the priority of research and development 
in National Institutes of Health, Institute of Medicine, the 
national assembly and others.6
Most previous studies on the cost of illness have dealt with 
major health risks like specific diseases2,7,8 or smoking,9-12 
alcohol-drinking13-15 and obesity16-18 and their relevant 
diseases. But, even though liver disease exerts not a few 
negative effect in South Korea with recording a high 
mortality rate especially in economically active age groups 
as one of major death causes, there has been nearly no study 
analyzing the socioeconomic burden of liver disease 
precisely in the country. Therefore, this study aims to 
estimate the socioeconomic costs of major liver diseases 
(viral infection, liver cirrhosis and others and HCC) for the 
last five years (2004-2008) to provide basic data for the 
public awareness of the importance of prevention and 
management of liver disease.
MATERIALS AND METHODS
Materials
Studies on the cost of illness have been described by 
several researchers since 1960s.6,19-21 Generally, studies on 
the cost of illness divide costs into direct, indirect and 
intangible ones and their viewpoints include a society, 
governmental institutions, employers, program providers 
and others. Most studies have measured the cost of illness 
from a societal perspective to consider its overall change 
comprehensively.22 This study selected viral hepatitis 
(B15-B19), liver cirrhosis and others (K70-K76) and HCC 
(C22) (Table 1) as representative liver diseases, and 
estimated their socioeconomic costs in 2004 to 2008 by 
classifying them into direct and indirect costs. 
Direct costs
The direct costs included direct medical costs and direct 
non-medical costs. The direct medical costs meant the sum 
of medical costs paid by outpatients and inpatients at 
medical institutions and at pharmacies to treat the liver 
disease. The total scale of treatment amount of Korean 
patients with liver disease can be investigated with health 
insurance data for items covered by the insurance at medical 
institutions and pharmacies. As the whole nation has been 
mandatorily insured through the national health insurance 
and a single system of health insurance claim data has been 
established in South Korea, various studies on cost of illness 
be conducted easily without an additional survey.23,24 This 
study estimated the medical costs for items covered by 
the insurance by calculating the treatment amount of 
liver disease for inpatients and outpatients at medical 
institutions and at pharmacies by gender, age and year based 
on the National Health Insurance Statistical Yearbook 
(Appendix 1).25 
 By considering that the rate of uninsured out-of-pocket 
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payments was 15.2%26 in 2008, the exclusion of uninsured 
items underestimates the direct medical costs eventually not 
to reflect a socioeconomic loss related with liver disease. 
Therefore, for uninsured items, the medical costs among 
direct medical costs were estimated by applying the copayment 
rate of non-benefit (Appendix 2) for the total treatment 
amount for inpatients and outpatients at medical institutions 
and at pharmacies to the total treatment amount of liver 
disease by gender, age and year.26
 The direct non-medical costs meant incidental expenses 
for the use of medical institutions or pharmacies, traffic 
costs for visits to clinics and costs of caregivers for 
inpatients. As the length of hospitalization and visiting days 
for medical service can be investigated as a whole, health 
insurance data are the most objective and comprehensive 
data to calculate direct non-medical costs. The traffic costs 
were estimated by multiplying the number of visit days of 
liver disease patients by gender and age by an average 
round-trip traffic cost per one visit. At this time, the number 
of visit days by gender and age was gained from the National 
Health Insurance Statistical Yearbook25 (Appendix 3) and 
the average round-trip traffic cost was calculated to be KRW 
1,191, KRW 1,251, KRW 1,309, KRW 1,356 and KRW 
1,475 in 2005 to 2008, respectively by applying the consumer 
price index of traffic costs27 to the average round-trip traffic 
cost per one visit to an outpatient clinic (KRW 1,475) in 
2008 Korean Health Panel Survey.28 In addition, costs of 
caregivers were regarded as personnel expenses of 
caregivers and opportunity costs of guardians of inpatients. 
The number of hospitalization days due to liver disease by 
gender and age was obtained from the National Health 
Insurance Statistical Yearbook25 (Appendix 3) and the daily 
average personnel expenses of caregivers (KRW 60,000) 
suggested by Korean caregiver societies was input as the 
personnel expenses of caregivers or the opportunity costs 
of guardians. The costs of caregivers of the patients were 
estimated by multiplying the personnel expenses by the 
number of hospitalization days.
Indirect costs
Indirect costs included lost earnings due to premature 
death caused by liver disease and loss of productivity 
following absences from work to visit medical institutions. 
The lost earnings due to premature death was estimated by 
multiplying the human loss per person by the number of 
deaths due to liver disease by gender and age and the period 
from the year after death to the average life expectancy by 
gender and age. The number of deaths due to liver disease 
was secured from Annual Report on the Cause of Death 
Statistics (Appendix 4) published annually by Statistics 
Korea. The human loss per person was calculated with the 
probability of survival, employment rate, average annual 
income and wage growth rate by gender and age in each year 
from the year after death to the average life expectancy 
(Appendix 5). Therefore, the lost earnings due to premature 
death was estimated with the number of deaths by gender 
and age from Annual Report on the Cause of Death 
Statistics,29 the average life expectancy and the survival rate 
by gender and age from Life Table,30 the employment rate by 
gender and age from Annual Report on the Economically 
Active Population Survey,31 the average annual real wage by 
gender and age from Basic Survey on Wage Structure32 and 
the real wage growth rate of industry by gender and age 
from Survey Report on the Wages and Working Hours at 
Establishments.33 At this time, this study applied a discount 
rate to convert future costs after premature death into the 
present values in each year and it reflected an individual 
time preference or an interest rate. The future costs were 
changed into the present values by dividing them by 5% 
discount rate.
The loss of productivity following absences from work to 
visit medical institutions to treat liver disease was calculated 
by gaining the numbers of hospitalization days and visit 
days due to liver disease by gender, age and year from 
the National Health Insurance Statistical Yearbook25 
(Appendix 3) and by multiplying the numbers by the 
average daily income by gender, age and year from Basic 
Survey on Wage Structure.32 Cost items for estimation, 
major indexes to calculate each cost item and sources of 
indexes are summarized in Table 2.
Methods
Direct costs (DC) consisted of direct medical costs such 
as expenses of insured and uninsured items for inpatients 
and outpatients at medical institutions and at pharmacies to 
treat liver disease and direct non-medical costs like traffic 
costs to visit medical institutions and costs of caregivers for 
inpatients. Therefore, as shown in the following formulas for 
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Table 2. Categories related to liver disease and data sources
Types 
of costs Categories Estimation variables Data sources
Direct 
costs
Direct medical 
costs
Benefit sector* Treatment amount of hospitalization, 
outpatient and pharmacy
National health insurance statistical yearbook,25 
Survey on the benefit coverage rate of national 
health insurance26
Non benefit 
sector
Treatment amount and non-benefit 
rate of hospitalization, outpatient 
and pharmacy
Direct 
non-medical 
costs
Transportation Outpatient visit day, Round-trip 
transportation cost
National health insurance statistical yearbook,25 
Report of Korea health panel survey28
Care-giver Hospitalization day, Average daily 
care-giver cost
Indirect 
costs
Future income loss due to 
premature death
Number of death, Survival rate, 
Employment rate, Average annual 
real wage, Growth rate of real 
wage, Discount rate
Annual report on the cause of death statistics,29 Life 
tables for Korea,30 Annual report on the 
economically active population survey,31 Basic 
survey on wage structure,32 Survey report on 
the wages and working hours at establishments33
Productivity loss resulting from 
absence from work
Hospitalization day, Outpatient 
visit day, Employment rate, 
Average daily wage
National health insurance statistical yearbook,25 
Annual report on the economically active population
survey,31 Basic survey on wage structure32
* It is composed costs burdened by insurer and by beneficiary.
estimation, the direct medical costs were estimated by 
summing the total treatment amount of inpatients (IP) and 
outpatients (OP) and at pharmacies (P) based on the health 
insurance data by gender, age and disease (Appendix 1) and 
the value of multiplying the total treatment amount by the 
rate of uninsured out-of pocket payments to the total 
treatment amount of each group (α, β, γ) (Appendix 2). In 
addition, the traffic costs were obtained by multiplying the 
number of visit days (OV) by gender, age and disease 
(Appendix 3) by the average round-trip traffic costs per one 
visit to outpatient clinic (MT), and the costs of caregivers 
were done by multiplying the number of hospitalization days 
by gender, age and disease (IV) (Appendix 3) by the daily 
average personnel expenses of caregivers (MC).
 






        





 ×





 ×
DC = direct costs
i = 1, 2, …, n disease, j = 1, 2 gender, k = 0, 1, …, n age 
IPijk = total treatment amount of inpatients of i, j 
and k in health insurance data
OPijk = total treatment amount of outpatients of i, j
and k in health insurance data
Pijk = total treatment amount at pharmacies of i, 
j and k in health insurance data
α = rate of uninsured out-of pocket payments to total 
treatment amount of inpatients
β = rate of uninsured out-of pocket payments to total 
treatment amount of outpatients
γ = rate of uninsured out-of pocket payments to total 
treatment amount at pharmacies
OVijk = number of visit days of i, j and k 
MTj = average round-trip traffic costs per one visit
to an outpatient clinic of j
IVijk = number of hospitalization days of i, j and k, MC = 
daily average costs of caregivers
Indirect costs included the lost earnings due to premature 
death by liver disease and the loss of productivity following 
absences from work to visit medical institutions. The lost 
earnings due to premature death could be determined by 
how to measure the human value and methods for the 
measurement were gross loss of output or human capital 
approach and net loss of output approach. The former 
278 The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
converts the total labor income of premature deaths into the 
present value and the latter deducts future consumption from 
the estimate of the former. 
Future income of premature deaths was estimated by 
applying the most common gross loss of output or human 
capital approach.34 So, the lost earnings of premature 
deaths due to liver disease were calculated by multiplying 
the human loss by gender and age (Appendix 5) obtained 
with the survival rate by gender and age (S), the employment 
rate (E), the yearly average real wage (YW), the real wage 
growth rate (WR) and the discount rate (r) by the number of 
deaths due to liver disease by gender, age and disease (D) 
(Appendix 4).
 




  ×××××  
HCC = lost earnings due to premature death
i = 1, 2, …, n disease, j = 1, 2 gender, k = 0, 1, …, n age, τ 
= years
Di,j,k = number of deaths of i, j and k
  = probability of survival of a person with j and k in 
k+τ
= employment rate of a person with j and k in k+τ
= yearly average real wage of a person with j
and k in k+τ 
   = real wage growth rate in k+τ, r = discount rate
The loss of productivity following absences from work to 
visit medical institutions to treat liver disease (PLC) was 
estimated by multiplying the sum of the number of 
hospitalization days by gender, age and disease (IV) and a 
third of the number of visit days (OV) (Appendix 3) by the 
employment rate by gender and age (E) and the daily 
average wage by gender and age (DW). At this time, to 
revise the difference in the loss of productivity between 
outpatients and inpatients, the rate of physician productivity 
for outpatients to that for inpatients suggested by Noh et 
al14 and Jung and Ko2 was applied. The number of non 
productive days was calculated by adding one third of the 
number of visit days to the number of hospitalization days.
  ××
PLC = loss of productivity following sick leave
i = 1, 2, …, n disease, j = 1, 2 gender, k = 0, 1, …, n age
IVijk = number of hospitalization days of i, j and k 
OVijk = number of visit days of i, j and k
Ejk = employment rate of j and k 
DWjk = daily average wage of j and k 
RESULTS
Direct costs
 The medical costs of inpatients and outpatients at 
medical institutions and at pharmacies to treat liver disease 
or the sum of benefits paid by the insurer, legal out-of pocket 
payments and uninsured out-of pocket payments, increased 
1.8 times from KRW 588.7 billion  in 2004 to KRW 1,032.2 
billion in 2008. For the costs by gender, those of males 
became 1.7 times from KRW 417.5 billion to KRW 724.3 
billion  and those of females did 1.8 times from KRW 171.2 
billion to KRW 307.9 billion, respectively for the same 
period. The medical costs of males and females accounted 
for 70.2% and 29.8% of the total costs, respectively in 2008 
and the rate of males was 2.4 times higher than that of 
females. The rate of medical costs by age recorded the 
highest level or 27.0-28.7% in the patients in their 50s, and 
those in their 40s (21.3-23.5%), 60s (21.1-22.0%), 30s 
(10.7-11.0%) and 70s (8.4-9.5%) (Table 3). 
Traffic costs went up 1.3 times from KRW 5.5 billion in 
2004 to KRW 7 billion in 2008. The traffic costs of males 
increased 1.3 times from 3.6 to KRW 4.5 billion and those of 
females did from KRW 1.9 billion  to KRW 2.5 billion, 
respectively for the same period. The rate of traffic costs was 
found to be 1.8 times higher in males than in female by 
recording 64.4% and 35.6%, respectively in 2008. The 
traffic costs by age accounted for the largest portion or 
23.1-25.6% in liver disease patients in their 40s, and those in 
their 50s (21.8-24.6%), 30s (15.8-17.1%), 60s (15.7-16.7%) 
and 20s (8.7-9.4%) (Table 4).
The personnel expenses of paid caregivers or the opportunity 
costs of guardians to care inpatients with liver disease 
increased 1.2 times from KRW 111.5 billion in 2004 to 
KRW 133 billion in 2008. The costs of males became higher 
1.2 times from KRW 82.9 billion to KRW 95.4 billion and 
those of females did 1.3 times from KRW 28.6 billion to 
KRW 37.7 billion, respectively. In addition, the rates of 
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Table 3. Direct medical costs related to liver disease (units: KRW 1,000,000, %)
2004 2005 2006 2007 2008
Male <10 1,830 0.4 2,115 0.5 2,018 0.4 2,102 0.3 2,404 0.3
10-19 5,111 1.2 5,548 1.2 5,519 1.1 6,004 0.9 6,509 0.9
20-29 18,793 4.5 21,924 4.7 24,934 4.8 28,882 4.5 34,844 4.8
30-39 45,585 10.9 50,670 10.9 57,449 11.1 71,029 11.1 81,248 11.2
40-49 106,053 25.4 114,954 24.7 125,232 24.1 150,287 23.4 165,158 22.8
50-59 116,747 28.0 132,826 28.5 152,168 29.3 191,676 29.9 213,519 29.5
60-69 88,944 21.3 97,310 20.9 106,325 20.5 131,657 20.5 150,574 20.8
70-79 29,417 7.1 34,788 7.5 39,491 7.6 50,954 8.0 59,697 8.2
≥80 5,027 1.2 5,862 1.3 6,616 1.3 8,528 1.3 10,323 1.4
Total 417,507 100.0 465,996 100.0 519,751 100.0 641,117 100.0 724,276 100.0
Female <10 1,408 0.8 1,480 0.8 1,381 0.7 1,567 0.6 1,828 0.6
10-19 2,429 1.4 2,560 1.4 2,770 1.3 2,971 1.1 3,697 1.2
20-29 10,337 6.0 12,062 6.4 14,363 6.8 16,209 6.1 20,141 6.5
30-39 17,502 10.2 19,902 10.5 21,594 10.2 26,630 10.0 32,187 10.5
40-49 32,148 18.8 35,605 18.8 39,874 18.8 48,513 18.3 54,439 17.7
50-59 42,147 24.6 46,485 24.5 52,795 24.9 68,222 25.7 79,026 25.7
60-69 40,348 23.6 43,799 23.1 48,180 22.7 60,805 22.9 68,949 22.4
70-79 20,207 11.8 22,729 12.0 25,425 12.0 32,237 12.2 38,227 12.4
≥80 4,666 2.7 5,205 2.7 5,852 2.8 8,017 3.0 9,444 3.1
Total 171,193 100.0 189,828 100.0 212,232 100.0 265,171 100.0 307,939 100.0
Overall <10 3,238 0.6 3,595 0.6 3,400 0.5 3,669 0.4 4,232 0.4
10-19 7,541 1.3 8,108 1.2 8,289 1.1 8,974 1.0 10,206 1.0
20-29 29,130 5.0 33,985 5.2 39,296 5.4 45,091 5.0 54,985 5.3
30-39 63,087 10.7 70,573 10.8 79,043 10.8 97,659 10.8 113,435 11.0
40-49 138,201 23.5 150,559 23.0 165,106 22.6 198,800 21.9 219,598 21.3
50-59 158,894 27.0 179,311 27.3 204,962 28.0 259,898 28.7 292,544 28.3
60-69 129,291 22.0 141,109 21.5 154,505 21.1 192,462 21.2 219,524 21.3
70-79 49,624 8.4 57,517 8.8 64,916 8.9 83,190 9.2 97,924 9.5
≥80 9,693 1.7 11,067 1.7 12,467 1.7 16,545 1.8 19,767 1.9
Total 588,700 100.0 655,824 100.0 731,984 100.0 906,288 100.0 1,032,215 100.0
costs of caregivers in male patients recorded 71.7% and 
28.3%, respectively in 2008 and the rate of males was 2.5 
times higher than that of females. The rate of costs of 
caregivers by age showed the highest level or 24.3-26.5% in 
the patients in their 50s, and those in their 60s (21.1-22.1%), 
40s (18.8- 23.7%), 70s (10.0-13.1%) and 30s (9.4-10.8%) 
(Table 5).
Indirect costs
Indirect costs included the lost earnings due to premature 
death caused by liver disease and the loss of productivity 
following absences from work. The lost earnings due to 
premature death reduced from KRW 4,925 billion in 2004 to 
KRW 4,205.1 billion in 2008 by 14.6% and the lost earnings 
of males declined from KRW 4,623.7 billion to KRW  
3,934.5 billion by 14.9% and those of females did from 
KRW 301.4 billion to KRW 270.6 billion by 10.2%, 
respectively. The rates of lost earnings in males and females 
with liver disease were 93.6% and 6.4%, respectively in 
2008, so the rate of males was 14.5 times higher than that of 
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Table 4. Transportation costs related to liver disease (units: KRW 1,000,000, %)
2004 2005 2006 2007 2008
Male <10 33 0.9 34 0.9 32 0.8 29 0.7 28 0.6
10-19 113 3.2 127 3.3 124 3.0 120 2.7 121 2.7
20-29 314 8.8 339 8.8 373 9.0 364 8.3 374 8.3
30-39 637 17.8 675 17.4 717 17.3 749 17.0 752 16.7
40-49 967 27.0 1,024 26.4 1,063 25.7 1,110 25.2 1,099 24.4
50-59 781 21.8 879 22.7 967 23.4 1,064 24.2 1,107 24.5
60-69 548 15.3 584 15.1 625 15.1 689 15.7 723 16.0
70-79 162 4.5 187 4.8 211 5.1 246 5.6 271 6.0
≥80 22 0.6 25 0.7 28 0.7 31 0.7 36 0.8
Total 3,578 100.0 3,874 100.0 4,139 100.0 4,401 100.0 4,510 100.0
Female <10 26 1.3 26 1.3 26 1.2 23 1.0 22 0.9
10-19 56 2.9 58 2.8 60 2.7 57 2.4 58 2.3
20-29 195 10.3 211 10.2 226 10.2 225 9.5 238 9.5
30-39 303 15.9 321 15.5 333 15.1 346 14.7 356 14.3
40-49 434 22.8 469 22.6 486 22.0 508 21.6 517 20.8
50-59 414 21.7 474 22.8 521 23.5 576 24.4 619 24.8
60-69 328 17.2 352 17.0 378 17.1 412 17.5 446 17.9
70-79 128 6.7 143 6.9 159 7.2 183 7.8 204 8.2
≥80 20 1.1 23 1.1 25 1.1 29 1.2 33 1.3
Total 1,905 100.0 2,078 100.0 2,215 100.0 2,359 100.0 2,493 100.0
Overall <10 59 1.1 60 1.0 58 0.9 52 0.8 50 0.7
10-19 169 3.1 185 3.1 183 2.9 176 2.6 179 2.6
20-29 509 9.3 550 9.3 599 9.4 589 8.7 611 8.7
30-39 940 17.1 996 16.7 1,050 16.5 1,095 16.2 1,108 15.8
40-49 1,401 25.6 1,494 25.1 1,549 24.4 1,619 24.0 1,616 23.1
50-59 1,195 21.8 1,353 22.7 1,487 23.4 1,640 24.3 1,726 24.6
60-69 876 16.0 936 15.7 1,003 15.8 1,100 16.3 1,170 16.7
70-79 290 5.3 330 5.6 370 5.8 429 6.3 475 6.8
≥80 43 0.8 48 0.8 53 0.8 60 0.9 69 1.0
Total 5,482 100.0 5,952 100.0 6,353 100.0 6,760 100.0 7,003 100.0
females. The rate by age recorded the highest level or 
39.4-44.0% in liver disease patients in their 40s, and those in 
their 50s (21.1-33.9%), 30s (9.1-22.2%), 60s (7.9-13.1%) and 
70s (1.1-3.5%). This showed the premature deaths in 
economically active age groups provoked a significant 
social loss of productivity (Table 6).
The scale of loss of productivity following absences from 
work to treat liver disease went up 1.4 times from KRW 
227.3 billion in 2004 to KRW 311.2 billion in 2008 and the 
scale of males was raised 1.3 times from KRW 183.8 billion 
to KRW 247.6 billion and those of females was 1.5 times 
from KRW 43.5 billion to KRW 63.6 billion, respectively 
for the same period. The rates of loss of productivity in 
males and females accounted for 79.6% and 20.4%, 
respectively in 2008 and that of males was found to be 3.9 
times higher than that of females. The loss of productivity by 
age recorded the highest level or 27.0-32.1% in liver disease 
patients in their 40s, and those in their 50s (26.7-30.0%), 60s 
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Table 5. Caregiver costs related to liver disease (units: KRW 1,000,000, %)
2004 2005 2006 2007 2008
Male <10 342 0.4 403 0.5 343 0.4 303 0.3 372 0.4
10-19 659 0.8 627 0.8 687 0.8 681 0.8 936 1.0
20-29 3,384 4.1 3,715 4.5 4,091 4.9 3,793 4.2 5,346 5.6
30-39 8,905 10.7 8,566 10.3 8,933 10.6 8,883 9.8 10,441 11.0
40-49 21,581 26.0 20,289 24.4 19,447 23.1 19,965 22.1 19,704 20.7
50-59 22,781 27.5 23,426 28.2 23,335 27.7 25,525 28.3 25,247 26.5
60-69 17,480 21.1 17,631 21.2 17,753 21.1 19,517 21.6 20,382 21.4
70-79 6,467 7.8 7,042 8.5 7,947 9.4 9,463 10.5 10,289 10.8
≥80 1,301 1.6 1,527 1.8 1,738 2.1 2,200 2.4 2,657 2.8
Total 82,899 100.0 83,227 100.0 84,274 100.0 90,331 100.0 95,375 100.0
Female <10 248 0.9 278 1.0 235 0.8 224 0.7 297 0.8
10-19 264 0.9 289 1.0 308 1.0 320 1.0 500 1.3
20-29 1,375 4.8 1,583 5.4 2,040 6.6 1,907 5.6 2,993 7.9
30-39 2,306 8.1 2,414 8.2 2,656 8.6 2,744 8.1 3,935 10.5
40-49 4,870 17.1 4,770 16.3 4,619 14.9 4,997 14.8 5,302 14.1
50-59 6,277 22.0 6,414 21.9 6,252 20.2 6,812 20.2 7,082 18.8
60-69 7,066 24.7 7,022 23.9 7,257 23.5 7,899 23.4 7,677 20.4
70-79 4,710 16.5 4,981 17.0 5,593 18.1 6,337 18.8 7,097 18.8
≥80 1,451 5.1 1,576 5.4 1,975 6.4 2,550 7.6 2,789 7.4
Total 28,566 100.0 29,327 100.0 30,935 100.0 33,790 100.0 37,673 100.0
Overall <10 590 0.5 680 0.6 578 0.5 527 0.4 669 0.5
10-19 922 0.8 916 0.8 994 0.9 1,002 0.8 1,436 1.1
20-29 4,759 4.3 5,298 4.7 6,131 5.3 5,700 4.6 8,339 6.3
30-39 11,210 10.1 10,981 9.8 11,589 10.1 11,627 9.4 14,377 10.8
40-49 26,451 23.7 25,059 22.3 24,066 20.9 24,962 20.1 25,006 18.8
50-59 29,059 26.1 29,840 26.5 29,587 25.7 32,337 26.1 32,329 24.3
60-69 24,545 22.0 24,653 21.9 25,010 21.7 27,416 22.1 28,059 21.1
70-79 11,177 10.0 12,023 10.7 13,540 11.8 15,800 12.7 17,387 13.1
≥80 2,752 2.5 3,104 2.8 3,714 3.2 4,750 3.8 5,446 4.1
Total 111,465 100.0 112,554 100.0 115,209 100.0 124,121 100.0 133,047 100.0
(14.1-15.2%), 30s (13.9-15.4%) and 70s (5.7-7.9%) (Table 7).
Overall costs
When all socioeconomic costs of liver disease for the last 
five years were put together, they recorded KRW 5,858 
billion, KRW 5,572.4 billion, KRW 8,104.3 billion, KRW 
6,095.2 billion and KRW 5,688.6 billion in 2004 to 2008, 
respectively. According to cost items, the lost earnings 
caused by liver disease-related premature death accounted 
for the largest portion of the total socioeconomic costs or 
73.9-86.1%, and the rates of direct medical costs, the loss of 
productivity following sick leave and direct non-medical 
costs such as traffic costs and costs of caregivers were 
9.0-18.1%, 3.3- 5.5% and 1.5-2.5%, respectively. In 
particular, the rate of lost earnings out of the total 
socioeconomic costs slightly decreased from 2004 to 2008 but 
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Table 6. Future income loss due to premature death related to liver disease (units: KRW 1,000,000, %)
2004 2005 2006 2007 2008
Male <10 14,618 0.3 12,436 0.3 10,407 0.2 7,757 0.2 2,834 0.1
10-19 6,103 0.1 3,820 0.1 11,975 0.2 5,584 0.1 5,433 0.1
20-29 46,797 1.0 47,830 1.1 206,939 3.2 33,442 0.8 30,262 0.8
30-39 592,777 12.8 459,006 10.8 1,460,125 22.4 415,465 9.3 347,706 8.8
40-49 2,075,455 44.9 1,868,067 44.0 2,922,508 44.9 1,937,486 43.5 1,578,378 40.1
50-59 1,290,001 27.9 1,252,887 29.5 1,359,083 20.9 1,404,538 31.6 1,350,872 34.3
60-69 515,947 11.2 508,438 12.0 478,007 7.3 535,303 12.0 494,823 12.6
70-79 81,967 1.8 91,478 2.2 61,793 1.0 112,891 2.5 124,199 3.2
Total 4,623,664 100.0 4,243,963 100.0 6,510,836 100.0 4,452,467 100.0 3,934,506 100.0
Female <10 2,588 0.9 1,979 0.6 1,040 0.2 2,600 0.8 1,118 0.4
10-19 2,673 0.9 2,593 0.8 3,768 0.8 1,691 0.5 1,288 0.5
20-29 10,625 3.5 12,287 4.0 28,656 6.1 10,130 3.3 6,764 2.5
30-39 41,264 13.7 47,154 15.2 88,517 18.8 43,874 14.1 33,107 12.2
40-49 92,915 30.8 97,800 31.6 147,442 31.3 84,617 27.2 78,624 29.1
50-59 78,259 26.0 76,998 24.9 111,820 23.7 86,067 27.7 74,526 27.5
60-69 56,849 18.9 53,409 17.2 71,884 15.3 60,419 19.4 53,926 19.9
70-79 16,181 5.4 17,654 5.7 17,872 3.8 21,870 7.0 21,266 7.9
Total 301,355 100.0 309,874 100.0 470,999 100.0 311,268 100.0 270,618 100.0
Overall <10 17,206 0.4 14,415 0.3 11,447 0.2 10,357 0.2 3,951 0.1
10-19 8,776 0.2 6,413 0.1 15,743 0.2 7,276 0.2 6,721 0.2
20-29 57,422 1.2 60,117 1.3 235,595 3.4 43,571 0.9 37,026 0.9
30-39 634,042 12.9 506,161 11.1 1,548,641 22.2 459,339 9.6 380,813 9.1
40-49 2,168,370 44.0 1,965,867 43.2 3,069,950 44.0 2,022,102 42.5 1,657,002 39.4
50-59 1,368,259 27.8 1,329,886 29.2 1,470,902 21.1 1,490,605 31.3 1,425,398 33.9
60-69 572,797 11.6 561,847 12.3 549,892 7.9 595,723 12.5 548,749 13.1
70-79 98,148 2.0 109,132 2.4 79,665 1.1 134,761 2.8 145,464 3.5
Total 4,925,019 100.0 4,553,837 100.0 6,981,835 100.0 4,763,735 100.0 4,205,124 100.0
the rate of direct medical costs or costs paid by health 
insurance sharply increased (Table 8).
Analysis on the socioeconomic costs of liver disease by 
gender and age revealed that 88.0-90.7% of the total costs 
were incurred in males, and the rate of patients with liver 
disease in their 40s showed the highest (34.9-41.2%) and the 
rates of those in their 50s and 30s followed it by recording 
22.0-32.4% and 9.8-20.7%, respectively. The costs of males 
were higher in those in their 40s (36.7-42.7%), 50s (21.8- 
33.3%) and 30s (9.5-21.2%) in the order and those of 
females were higher in those in their 50s (23.8-26.2%), 40s 
(22.3-26.5%) and 60s (17.8-20.9%) in the order (Table 9).
DISCUSSION
 Liver disease is one of major death causes in South Korea 
and the number of deaths caused by it tends to be high in 
economically active age groups as a representative disease 
provoking a significant loss of productivity due to premature 
death. In 2001, liver disease ranked fifth among death causes 
in South Korea but its loss of productivity due to premature 
death was found to be the highest except cancer which is the 
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Table 7. Productivity loss resulting from absence from work related to liver disease (units: KRW 1,000,000, %)
2004 2005 2006 2007 2008
Male 10-19 1,441 0.8 1,563 0.8 1,651 0.8 1,530 0.7 1,488 0.6
20-29 6,923 3.8 7,930 4.0 8,970 4.2 8,537 3.6 10,259 4.1
30-39 27,496 15.0 28,973 14.7 30,629 14.3 31,784 13.5 34,725 14.0
40-49 62,796 34.2 64,339 32.7 66,780 31.1 71,473 30.3 71,140 28.7
50-59 51,136 27.8 57,456 29.2 65,044 30.3 74,256 31.5 76,184 30.8
60-69 25,313 13.8 26,652 13.5 29,724 13.8 33,663 14.3 36,775 14.9
70-79 8,715 4.7 9,915 5.0 12,170 5.7 14,845 6.3 17,012 6.9
Total 183,820 100.0 196,828 100.0 214,969 100.0 236,089 100.0 247,582 100.0
Female 10-19 722 1.7 823 1.7 920 1.7 929 1.6 999 1.6
20-29 3,770 8.7 4,296 9.1 4,940 9.2 4,768 8.2 5,917 9.3
30-39 7,488 17.2 8,126 17.2 8,778 16.3 9,183 15.8 10,965 17.2
40-49 10,048 23.1 11,022 23.3 11,787 21.8 12,400 21.3 12,971 20.4
50-59 9,518 21.9 10,805 22.8 12,170 22.5 13,909 23.9 14,548 22.9
60-69 7,712 17.7 7,816 16.5 9,537 17.7 10,352 17.8 10,602 16.7
70-79 4,212 9.7 4,489 9.5 5,863 10.9 6,696 11.5 7,613 12.0
Total 43,469 100.0 47,378 100.0 53,995 100.0 58,236 100.0 63,615 100.0
Overall 10-19 2,163 1.0 2,386 1.0 2,571 1.0 2,458 0.8 2,487 0.8
20-29 10,694 4.7 12,227 5.0 13,911 5.2 13,305 4.5 16,177 5.2
30-39 34,984 15.4 37,100 15.2 39,407 14.7 40,967 13.9 45,690 14.7
40-49 72,843 32.1 75,361 30.9 78,567 29.2 83,873 28.5 84,111 27.0
50-59 60,654 26.7 68,261 28.0 77,215 28.7 88,165 30.0 90,732 29.2
60-69 33,025 14.5 34,467 14.1 39,261 14.6 44,015 15.0 47,376 15.2
70-79 12,927 5.7 14,405 5.9 18,032 6.7 21,541 7.3 24,625 7.9
Total 227,290 100.0 244,206 100.0 268,963 100.0 294,325 100.0 311,198 100.0
number one death cause. Although liver disease leads to a 
considerable socioeconomic loss in the country like this, 
basic studies to establish liver disease-related health insurance 
policies are insufficient. Therefore, this study was conducted 
to provide basic data for policy making for the prevention 
and the management of liver disease in the future by 
estimating the socioeconomic costs of major liver diseases 
for the last five years from a societal perspective.
Liver diseases analyzed in this study were viral hepatitis 
(B15-B19), liver cirrhosis and other liver disease (K70-K76) 
and HCC (C22) and the costs of them were estimated by 
dividing them largely into direct and indirect costs. The 
directs costs contained the treatment amount covered and 
not covered by health insurance for inpatients and outpatients 
at medical institutions and at pharmacies, the traffic costs to 
visit medical institutions and the personnel expenses of 
caregivers or the opportunity costs of guardians for inpatients. 
The indirect costs did the lost earnings caused by liver 
disease-related premature death and the loss of productivity 
following absences from work to visit medical institutions.
According to the results, the socioeconomic costs of liver 
disease were estimated to be KRW 5,858 billion, KRW 
5,572.4 billion, KRW 8,104.3 billion, KRW 6,095.2 billion 
and KRW 5,688.6 billion from 2004 to 2008, respectively. 
By the cost items, the lost earnings caused by liver 
disease-related premature death accounted for the largest 
portion of the total costs or 73.9-86.1%, and the direct 
medical costs (9.0-18.1%), the loss of productivity 
following sick leave (3.3-5.5%) and the traffic costs and 
the costs of caregivers (1.5-2.5%) followed it in the order. 
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Table 8. Socioeconomic costs of liver disease (units: KRW 1,000,000, %)
Categories 2004 2005 2006 2007 2008
Direct
costs
Direct 
medical 
costs
Benefit sector* 467,088 8.0 525,685 9.4 615,357 7.6 770,622 12.6 857,822 15.1
Non benefit 
sector
121,612 2.1 130,139 2.3 116,627 1.4 135,666 2.2 174,393 3.1
Subtotal 588,700 10.0 655,824 11.8 731,984 9.0 906,288 14.9 1,032,215 18.1
Direct 
non-
medical 
costs
Transportation 5,482 0.1 5,952 0.1 6,353 0.1 6,760 0.1 7,003 0.1
Care-giver 111,465 1.9 112,554 2.0 115,209 1.4 124,121 2.0 133,047 2.3
Subtotal 116,948 2.0 118,506 2.1 121,563 1.5 130,881 2.1 140,050 2.5
Subtotal 705,648 12.0 774,330 13.9 853,547 10.5 1,037,169 17.0 1,172,266 20.6
Indirect 
costs
Future income loss
due to premature death
4,925,019 84.1 4,553,837 81.7 6,981,835 86.1 4,763,735 78.2 4,205,124 73.9
Productivity loss
resulting from
absence from work
227,290 3.9 244,206 4.4 268,963 3.3 294,325 4.8 311,198 5.5
Subtotal 5,152,308 88.0 4,798,044 86.1 7,250,798 89.5 5,058,060 83.0 4,516,322 79.4
Total 5,857,956 100.0 5,572,374 100.0 8,104,345 100.0 6,095,229 100.0 5,688,587 100.0
* It is composed costs burdened by insurer and by beneficiary.
Out of the total socioeconomic costs of liver disease, 
88.0-90.7% were incurred in males, and the costs by age 
showed higher rate in the patients in their 40s (34.9-41.2%), 
50s (22.0-32.4%) and 30s (9.8-20.7%) in the order. 
A study of Jung and Ko2 estimated the socioeconomic 
costs of the top five diseases for death causes in South Korea 
by classifying the costs into direct and indirect costs. In their 
study, the direct costs included medical expenditures, traffic 
costs and costs of guardians and the indirect costs did costs 
of lost workdays due to illness and lost earnings due to 
premature death. They reported that the costs of cancer 
(malignant neoplasm) or number one death cause, cerebrova-
scular disease, heart disease, diabetes and liver disease were 
KRW 7,735.8 billion, KRW 2,313.8 billion, KRW 2,141.7 
billion, KRW 1,158.8 billion and KRW 2,620.1 billion, 
respectively. For liver disease, the lost earnings due to 
premature death accounted for 88.3% of the total costs and 
rates of the medical expenditures of inpatients and 
outpatients, the costs of lost workdays, the costs of 
caregivers and the traffic costs recorded 7.7%, 2.4%, 1.1% 
and 0.5%, respectively.
In the comparison of the results between their study and 
this one, the study of Jung and Ko2 showed that the socioeconomic 
costs of liver disease were estimated to be KRW 2,620.1 
billion in 2001 while this study found that the costs were 
done to be KRW 5,858 billion in 2004, so the difference in 
the costs was significant. That is considered to result from 
not only the difference in the year of estimation and the 
methodologies but also the exclusion of the costs at 
pharmacies, which accounted for a considerable portion in 
the total costs, in the study of Jung and Ko.2 But, the finding 
that the rate of lost earnings due to premature death recorded 
the highest level among the socioeconomic costs of liver 
disease and the lost earnings by age showed the highest rates 
in economically active persons in their 30s, 40s and 50s, 
tended to be similar in both of the two studies and it led to a 
large influence on the loss of productivity in the society at 
large.
In addition, studies estimating the socioeconomic costs of 
disease have been reported continuously in Canada since 
1986. A study calculating the socioeconomic costs by classifying 
total disease into 20 groups such as cardiovascular disease, 
musculoskeletal disease and cancer with the data in 1998 
was published.34 The study in Canada34 largely divided the 
costs of diseases into direct and indirect costs, and the direct 
costs included treatment amount at medical institutions, 
drug expenditures and doctor bills and the indirect costs 
contained death costs and costs of prevalence of short- and 
long-term disorder. According to its results, although it did 
not examine liver disease specifically, the direct and indirect 
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Table 9. Socioeconomic costs of liver disease stratified according to sex and age group (units: KRW 1,000,000, %)
2004 2005 2006 2007 2008
Male <10 16,823 0.3 14,988 0.3 12,800 0.2 10,191 0.2 5,638 0.1
10-19 13,427 0.3 11,685 0.2 19,956 0.3 13,919 0.3 14,487 0.3
20-29 76,211 1.4 81,738 1.6 245,307 3.3 75,018 1.4 81,085 1.6
30-39 675,400 12.7 547,890 11.0 1,557,853 21.2 527,910 9.7 474,872 9.5
40-49 2,266,852 42.7 2,068,673 41.4 3,135,030 42.7 2,180,321 40.2 1,835,479 36.7
50-59 1,481,446 27.9 1,467,474 29.4 1,600,597 21.8 1,697,059 31.3 1,666,929 33.3
60-69 648,232 12.2 650,615 13.0 632,434 8.6 720,829 13.3 703,277 14.0
70-79 126,728 2.4 143,410 2.9 121,612 1.7 188,399 3.5 211,468 4.2
≥80 6,350 0.1 7,414 0.1 8,382 0.1 10,759 0.2 13,016 0.3
Total 5,311,468 100.0 4,993,888 100.0 7,333,969 100.0 5,424,405 100.0 5,006,249 100.0
Female <10 4,270 0.8 3,763 0.7 2,682 0.3 4,414 0.7 3,265 0.5
10-19 6,144 1.1 6,323 1.1 7,826 1.0 5,968 0.9 6,542 1.0
20-29 26,302 4.8 30,439 5.3 50,225 6.5 33,239 5.0 36,053 5.3
30-39 68,863 12.6 77,917 13.5 121,878 15.8 82,777 12.3 80,550 11.8
40-49 140,415 25.7 149,666 25.9 204,208 26.5 151,035 22.5 151,853 22.3
50-59 136,615 25.0 141,176 24.4 183,558 23.8 175,586 26.2 175,801 25.8
60-69 112,303 20.5 112,398 19.4 137,236 17.8 139,887 20.9 141,600 20.8
70-79 45,438 8.3 49,996 8.6 54,912 7.1 67,323 10.0 74,407 10.9
≥80 6,137 1.1 6,804 1.2 7,852 1.0 10,596 1.6 12,266 1.8
Total 546,488 100.0 578,485 100.0 770,376 100.0 670,824 100.0 682,338 100.0
Overall <10 21,093 0.4 18,750 0.3 15,483 0.2 14,605 0.2 8,902 0.2
10-19 19,571 0.3 18,008 0.3 27,780 0.3 19,886 0.3 21,029 0.4
20-29 102,514 1.7 112,177 2.0 295,532 3.6 108,256 1.8 117,138 2.1
30-39 744,263 12.7 625,811 11.2 1,679,730 20.7 610,687 10.0 555,423 9.8
40-49 2,407,266 41.1 2,218,340 39.8 3,339,238 41.2 2,331,356 38.2 1,987,333 34.9
50-59 1,618,061 27.6 1,608,651 28.9 1,784,153 22.0 1,872,645 30.7 1,842,729 32.4
60-69 760,534 13.0 763,012 13.7 769,671 9.5 860,716 14.1 844,878 14.9
70-79 172,166 2.9 193,407 3.5 176,523 2.2 255,721 4.2 285,875 5.0
≥80 12,488 0.2 14,219 0.3 16,234 0.2 21,355 0.4 25,282 0.4
Total 5,857,956 100.0 5,572,373 100.0 8,104,345 100.0 6,095,229 100.0 5,688,587 100.0
costs of the digestive disease including liver disease accounted 
for 4.2% (USD 3.54 billion) and 3.1% (USD 2.31) of the 
costs of total diseases and their sum recorded 7.3% (USD 
5.85 billion). As the study in Canada found that the weight of 
direct costs incurred by visiting medical institutions directly 
to treat digestive disease were estimated to be larger than 
that of indirect costs such as death costs, the finding was 
different from that of Korean studies investigating only liver 
disease.
This study is meaningful as the latest study on estimation 
of the socioeconomic costs of liver disease for the longest 
period. Moreover, because it calculated the costs from a 
societal perspective, it included the extensive effect of liver 
disease on the society at large. In particular, all Koreans have 
been insured mandatorily and the country has established a 
single insurance claim system so that the total scale of 
healthcare utilization except uninsured items can be grasped 
when liver disease patients utilize medical institutions or 
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pharmacies. As this study used these health insurance data to 
estimate direct medical costs, direct non-medical costs (traffic 
costs, costs of caregivers) and the loss of productivity 
following sick leave, the validity and the reliability of results 
of this study were expected to be enhanced. However, for 
direct medical costs, uninsured items not paid by the health 
insurance system needed to be included to calculate actual 
costs exactly but this study gained the uninsured medical 
costs by estimating them with the rate of uninsured out-of 
pocket payments26 in South Korea published by National 
Health Insurance Corporation every year since 2004. But, 
the data had a limitation that they did not include those about 
packs of prepared herb medicine in the oriental medicine 
and health improving agents like vitamin supplements at 
pharmacies. Although this study utilized the best available 
data and methodology to enhance the reliability and the 
utilization of the results, it had some limitations as follows.
First, in the process of investigating the healthcare utilization 
with the health insurance data related to liver disease, the 
data were extracted with only principal diagnosis as a standard 
with excluding liver disease as additional diagnosis, so the 
directs costs and the loss of productivity following sick 
leave could be underestimated. Second, costs of driving cars 
to visit outpatient clinics due to liver disease were excluded 
from the mean traffic costs so that the average round-trip 
traffic costs per one visit to an outpatient clinic could be 
underestimated. Third, for costs of caregivers for inpatients 
with liver disease, the nursing of guardians or paid caregivers 
might be determined by the severity of disease and the costs 
of caregivers could be incurred at home as well as at medical 
institutions. However, because of no data about the rate of 
the care-giving at home and the correlation between the 
severity of disease and the utilization rate of care-giving 
service, this study limited cases to calculate the costs of 
caregivers to inpatients at medical institutions, so the costs 
of caregivers was estimated on the assumption that the 
inpatients needed full-time care-giving. Fourth, in the 
process of estimating the future income loss due to premature 
death caused by liver disease and the loss of productivity 
following sick leave, this study analyzed only employees 
with income except unemployed persons (job seekers) and 
economically inactive population (housewives, students and 
persons waiting to enter the army) among the working-age 
group aged over 15 years to calculate the scale of objective 
and valid income loss. So, the exclusion of unpaid 
productive activities of unemployed persons and economically 
inactive population could underestimate the loss of productivity 
following premature deaths and sick leave, but objective and 
valid data to investigate the rate of the population and the 
economic value of the unpaid activities were insufficient. 
Fifth, the loss of productivity following sick leave contained 
the decreased or lost income of employed liver disease 
patients due to hospitalization or visits to medical institutions. 
However, a simple rest at home or other places during sick 
leave by the severity of disease was excluded in this study 
because of no data about the population, so the loss of 
productivity following sick leave could be underestimated. 
Lastly, the health insurance data are collected based on 
claims submitted to National Health Insurance Corporation 
by healthcare providers to receive costs paid by the insurer 
among the total costs of patients. Therefore, validity issues 
related with diagnosis and the content of medical service in 
the health insurance data have been raised continuously and 
particularly up-coding of reporting wrong disease codes 
intentionally works as a factor hampering the reliability of 
studies using the data. However, despite these fundamental 
limitations of the health insurance data, this study is 
considered to have relatively less up-coding inducing factors 
by analyzing liver disease or one of comparatively severe 
diseases and some up-coding related errors within liver 
disease are thought not to influence the results of this study 
considerably because this study analyzed the total liver 
disease not a part of the disease.
In conclusion, the socioeconomic costs of liver disease, 
although they were slightly different by year, were as much 
as maximally KRW 8,104.3 billion in 2006. The lost 
earnings caused by liver disease-related premature deaths 
accounted for the largest portion or 73.9-86.1%. However, 
while the rate of lost earnings tended to reduce slightly from 
2004 to 2008, the rate of direct medical costs paid by health 
insurance increased sharply. These findings meant that 
measures to improve the efficiency of the medical costs of 
liver disease are necessary. 
Moreover, 88.0-90.7% out of the socioeconomic costs of 
liver disease were incurred in males, and the costs by age 
recorded the highest rate or 34.9-41.2% of the total costs in 
liver disease patients in their 40s and those in their 50s 
(22.0-32.4%) and 30s (9.8-20.7%) followed them in the 
order. That shows that liver disease provokes a significant 
loss in most economically active age groups, and if appropriate 
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measures for the management of liver disease are not 
prepared, not only the loss of productivity in the society at 
large but also various potential loss are expected to be raised. 
Lastly, the results of this study are considered to be useful 
for promoting the public awareness of the urgency of the 
prevention and the management of liver disease and for 
prioritizing disease-related policies in various health projects.
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Appendix 2. Ratio of treatment cost to nonbenefit cost (unit: %)*
2004 2005 2006 2007 2008
Inpatient 40.25 40.00 27.75 25.00 30.38
Outpatient 20.63 18.76 17.37 19.90 21.07
Pharmacy 2.04 2.77 1.42 1.32 2.04
* source: Choi et al (2009).26
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Appendix 4. Deaths related to liver disease (units: persons)*
2004 2005 2006 2007 2008
Male Female Male Female Male Female Male Female Male Female
0-4 10 2 9 4 6 2 9 2 5 5
5-9 5 4 5 1 3 0 1 5 1 0
10-14 2 2 3 2 1 1 1 1 1 1
15-19 4 4 1 4 9 6 5 3 7 3
20-24 14 8 11 13 40 18 10 9 10 9
25-29 33 19 38 18 138 42 24 16 28 11
30-34 158 47 137 57 425 92 101 48 95 38
35-39 585 94 433 102 1,110 153 386 90 372 82
40-44 1,545 207 1,277 204 2,153 275 1,098 132 973 143
45-49 2,347 282 2,172 305 2,287 350 2,127 269 1,915 268
50-54 2,351 348 2,244 361 2,071 399 2,227 346 2,280 357
55-59 2,318 431 2,161 399 1,961 514 2,024 387 2,108 325
60-64 2,325 621 2,227 586 1,909 654 1,915 522 1,811 454
65-69 1,931 701 1,925 668 1,381 698 1,953 684 1,972 733
70-74 1,267 645 1,388 716 825 609 1,444 714 1,598 706
75-79 774 607 800 592 455 443 886 630 962 654
80-84 477 394 445 449 168 181 484 465 511 481
≥85 182 285 202 277 52 71 271 295 284 339
Total 16,328 4,701 15,478 4,758 14,994 4,508 14,966 4,618 14,933 4,609
* source: Statistics Korea (2005-2009).29
Appendix 5. Human capital loss per capita stratified according to sex, age, and year (units: KRW 1,000)
2004 2005 2006 2007 2008
Male Female Male Female Male Female Male Female Male Female
0-4 968,308 425,852 875,773 392,670 1,150,825 520,012 770,284 353,901 461,151 223,537
5-9 986,965 434,057 910,882 407,977 1,167,408 527,504 824,514 378,469 527,880 255,883
10-14 1,005,981 442,420 946,390 423,881 1,184,229 535,105 881,750 404,742 604,265 292,909
15-19 1,022,649 447,124 980,551 436,326 1,198,926 538,834 940,491 428,866 689,770 331,648
20-24 1,020,378 426,258 996,153 421,658 1,196,189 515,191 982,463 426,849 766,912 347,817
25-29 985,190 379,732 970,326 378,070 1,152,840 461,484 984,042 393,007 806,887 330,310
30-34 898,009 328,001 892,466 329,099 1,054,007 400,784 932,171 349,329 795,551 300,466
35-39 770,756 274,979 777,687 278,387 911,866 337,546 832,425 301,180 731,529 264,508
40-44 623,103 220,161 635,710 224,194 745,922 272,020 702,206 247,549 628,695 221,439
45-49 474,120 167,878 486,310 170,704 575,661 207,534 548,408 193,086 504,782 175,218
50-54 332,101 121,448 341,122 121,998 404,743 148,854 396,079 140,823 368,474 128,652
55-59 219,686 83,515 225,548 82,599 265,609 101,998 258,137 96,491 242,292 87,991
60-64 143,247 53,320 145,084 52,639 169,758 65,432 165,948 62,381 156,550 57,132
65-69 94,716 33,862 96,278 33,777 111,470 41,679 111,374 40,726 107,156 38,183
70-74 55,125 19,779 56,567 19,920 64,770 24,310 66,364 24,364 65,880 23,573
75-79 15,663 5,640 16,204 5,729 18,367 6,923 19,258 7,101 19,671 7,069
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